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Abstract
New protocols based on ALK-targeted therapy by crizotinib or other ALK-tar-
geting molecules have opened for the treatment of patients with neuroblastoma
(NB) if their tumors showed mutation and/or amplification of the ALK gene.
However, tumor samples are not always available for analysis of ALK muta-
tional status in particular at relapse. Here, we evaluated the ALK mutational
status of NB samples by analysis of circulating DNA, using the droplet digital
PCR (ddPCR) system. ddPCR assays was developed for the detection of ALK
mutations at F1174 and R1275 hotspots found in NB tumors and was applied
for the analysis of circulating DNA obtained from 200 lL of serum or plasma
samples collected from 114 patients with NB. The mutations F1174L (exon 23
position 3520, T>C and position 3522, C>A) and the mutation R1275Q (exon
25 position 3824, G>A) were detected in circulating DNA. The sensitivity of
our test was 100%, 85%, and 92%, respectively, and the specificity was 100%,
91%, and 98%, respectively. In conclusion, the assay that we have developed
offers a reliable, noninvasive blood test to assess ALK mutational status at
F1174 and R1275 hotspots and should help clinicians to identify patients show-
ing an ALK mutation in particular when no tumor tissue is available.
Introduction
Neuroblastoma (NB), the most frequent extracranial solid
tumor of childhood, is characterized by wide clinical vari-
ability, with possible cellular maturation or spontaneous
tumor regression on the one hand, or aggressive clinical
behavior with rapid progression despite intensive thera-
peutic approaches on the other hand. The International
Neuroblastoma Risk Group (INRG) currently stratifies
patients into very low, low, intermediate, or high-risk cat-
egories based upon well-defined prognostic factors [1].
These include patient’s age at diagnosis, disease stage,
histopathological diagnosis, and MYCN oncogene status.
Furthermore, the presence of several genetic copy number
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alterations observed recurrently in NB tumors (deletion
of 1p, 3p, 4p, and 11q and/or gain 1q, 2p, and 17q) have
been shown to be of prognostic impact [2]. Despite the
extensive description of copy number alterations in NB,
few single gene alterations have been shown to be driver
mutations in NB oncogenesis. Activating mutations of the
ALK tyrosine kinase receptor have been shown to occur
in ~8–10% of cases at diagnosis. To date, over 50
different ALK mutations affecting 12 different AA residues
have been described, with two major hotspots at position
1174 and 1275 [3–7]. These two hotspots are involved in
70% of ALK mutations [8]. In vitro and in vivo NB mod-
els studies have indicated the potential usefulness of ALK
inhibitors in the presence of an activating ALK mutation
[9–11] and a phase 1/2 study of crizotinib, a dual ALK/
MET inhibitor, supports further investigation of efficacy
in the subset of NB harboring ALK mutations [12].
The ddPCR (droplet digital PCR) is a highly sensitive
recently developed technology [13], enables the absolute
quantitation of nucleic acids in a sample and allows
the detection of rare mutant alleles and the identifica-
tion of mutational status of a patient’s cancer after
assessment of circulating tumor DNA (ctDNA) in cell-
free plasma [14].
Few years ago, we and others have demonstrated the
presence of circulating MYCN sequences in the peripheral
blood of patients with NB [15–19]. Based on these observa-
tions and as mutations of the ALK tyrosine kinase domain
constitute an important potential therapeutic target, a pro-
gram to identify the presence of ALK mutation in the
peripheral blood of NB patients showing a high risk of
relapse [20] was initiated: the F1174 and R1275 hotspots of
ALK gene were investigated using the ddPCR system.
Material and Methods
Patient population and samples
Patients diagnosed with NB were enrolled in the study after
obtaining informed consent from their parents, according
to national law. This study was authorized by the ethics
committees “Comite de Protection des Personnes Sud-Est
IV,” L07-95 and L12-171, as well as “Comite de Protection
des Personnes de Paris Ile de France I” ref 08-11728. Serum
or plasma from 114 patients with NB was assayed by
ddPCR. For a majority of cases, the ALK status of the
tumor was defined previously by Sanger sequencing (exons
23–25). Samples (serum, plasma, and tumors) were
obtained from patients classified as stage 2 (n = 1, case
with MYCN amplification), stage 3 (n = 16 whose six cases
showed a MYCN amplification), and stage 4 (n = 97)
according to the INSS classification [21]. All of them were
collected at diagnosis except for one obtained at relapse.
Serum or plasma samples were prepared by centrifugation
of blood at 700 g for 10 min followed by careful aliquoting
and freezing at 80°C. The storage of samples was per-
formed 1–24 h after the collection.
DNA isolation
Tumor DNA and normal DNA were extracted from
frozen NB and lymphocytes samples using phenol
chloroform, and circulating DNA was extracted from
200 lL of plasma or serum using the QIAmp DNA mi-
crokit (Qiagen, Courtaboeuf, France) according to the
plasma protocol recommended by the manufacturer.
Sequencing of tumor and normal DNA
Sanger sequencing was performed on 101 tumor DNA
samples. All of them contained more than 50% of tumor
cells as confirmed by pathological analysis. After amplifica-
tion of ALK exons 23–25, PCR products were purified with
Illustra Exostar (GE Healthcare Europe GmbH, Velizy-Vil-
lacoublay, France) for 15 min at 37°C and 15 min by
80°C. A sequencing reaction was set up with 1 ll of puri-
fied PCR products and the BigDye Terminator v1.1 Cycle
Sequencing Kit (Life Technologies, Saint Aubin, France)
following the manufacturer’s instructions. The purification
of the DNA sequencing reactions was performed by precip-
itation with ethanol and washing with 70% ethanol for
removing nonincorporated BigDye terminators and salts.
DNA was dissolved in 30 lL of ultrapure water and incu-
bated for 10 min with agitation of 900 rpm. Sequencing
analyses were carried out on the 48 capillary 3730 DNA
Analyzer (Life Technologies). The primers used are
described in Table 1. To define if the mutation detected on
tumor DNA samples was germline or somatic ALK muta-
tions, the normal DNA samples obtained from lympho-
cytes of NB patients showing ALK mutations were studied.
ddPCR
The droplet digital PCR (ddPCR) workflow requires dif-
ferent steps involving droplet generation, the PCR proce-
dure, and the droplet reading [13] (Fig. 1). Five
microliters of circulating DNA or 5 lL of tumor DNA
sample (10 ng/lL) was added to 14 lL of Droplet PCR
Supermix (Bio-Rad Technologies, Marnes-la-Coquette,
France) and 1 lL of the primer/probe mixture. This
20 lL sample was added to 70 lL of Droplet Generation
Oil (Bio-Rad Technologies) and used for droplet genera-
tion. Droplets were then thermal cycled as follows:
10 min at 95°C, 40 cycles of 94°C for 30 sec, 55°C (for
ALK F1174L) or 62°C (for ALK R1275Q) for 1 min fol-
lowed by 98°C for 10 min. Samples were then transferred
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to a QX100 digital droplet reader (Bio-Rad Technologies)
for fluorescent measurement of FAM and VIC or HEX
probes. Each sample was analyzed in duplicate. The prim-
ers and the probe targeting the hotspot F1174L (3520,
T>C) were purchased from Biorad, whereas the primers
and the probes specific for the hotspots F1174L (3522,
C>A) and R1275Q (3824, G>A) were designed using Pri-
mer3Plus software and are described in Table 1. They
were used to a final concentration of 900 and 250 nmol/
L, respectively. Each experiment contained positive and
negative controls as well as no template controls. The
cases showing a mutation were confirmed in a second
experiment. Droplets were scored as positive or negative
based upon their fluorescence intensity which was deter-
mined by gating a threshold using positive and negative
controls as well as no template controls. Although in the-
ory, one positive droplet should score the sample as posi-
tive, a minimal number of six positive droplets was
defined to classify a sample as positive. A plasma sample
was described as evaluable only if greater than 100 events
(mutated+wild type [WT]) can be identified for each hot-
spot analyzed.
Deep sequencing of ALK exon 23 and exon
25 regions with Illumina HiSeq2500
technology
Fifty nanograms of genomic DNA from each sample was
amplified via a two-step PCR approach. In the first step,
the ALK regions of interest containing F1174 and R1275
Table 1. Primer sets and probes used for PCR in this study.
Primers for Sanger sequencing
ALK-23F Primer GCC-CAG-ACT-CAG-CTC-AGT-TA
ALK-23R Primer CAT-CCT-TGC-TCC-TGT-CCT-TG
ALK-ex25F Primer CCT-AGT-GAT-GGC-CGT-TGT-ACA-C
ALK-ex25R Primer GTA-CCA-GGA-GAT-GAT-GTA-AGG-GAC-AAG
Primers and probes for ddPCR
ALK-1275-M Probe 6-FAM-TTC-GGG-ATG-GCC-CAA-GAC-AT-MGB
ALK-1275-W Probe VIC-TTC-GGG-ATG-GCC-CGA-GAC-AT-MGB
ALK-F1174L3522-M Probe 6FAM-TCT-CTG-CTC-TGC-AGC-AAA-TTA-AAC-C-MGB
ALK-F1174L3522-WT Probe VIC-TCT-CTG-CTC-TGC-AGC-AAA-TTC-AAC-C-MGB
ALK-F1174L3522-F Primer GCC-CAG-ACT-CAG-CTC-AGT
ALK-F1174L3522-R Primer CCC-CAA-TGC-AGC-GAA-CAA-T
ALK-1275-F Primer GTC-CAG-GCC-CTG-GAA-GAG
ALK-1275-R Primer GGG-GTG-AGG-CAG-TCT-TTA-CTC
The ALK F1174L3520 probes and primers were purchased from Biorad and the sequences were not known.
Figure 1. Illustration of different steps of droplet digital PCR (ddPCR) workflow.
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hotspots were amplified. The second PCR step consisted
of addition of sample-specific barcodes for targeted rese-
quencing in a single experiment. Amplicon sequencing
(Illumina HiSeq2500, Eindhoven, the Netherlands)
achieved an extremely high depth of coverage over the
relevant hotspot (>80,000X). The background base
variability (error rate) in 24 germline control samples
was below 0.01% at the 3520, 3522, and 3824 position,
respectively.
For each sample, the frequencies of the bases at the
given position were then compared to those observed in
the 24 controls. Statistical analyses were performed with
the R statistical software (http://www.R-project.org). Fish-
er’s exact two-sided tests were performed to compare per-
centages of bases between the data sets, that is, between a
case and the controls.
Statistical methods
The dichotomous results obtained by ddPCR from plasma
and tumor samples were cross-tabulated. The sensitivity
and the specificity were calculated according to the crite-
ria published by Delacour et al. [22].
Results
ALK mutation detection in circulating DNA
by ddPCR
Among the 114 serum or plasma samples studied, 111
cases were described as evaluable. No mutation was
detected in 87 samples, whereas 24 cases were found
mutated (Table 2) (Fig. 2). Mutant to WT ALK ratio ran-
ged from 0.15% to 43.7% and the prevalence of ALK
mutations detected in circulating DNA samples by ddPCR
was 21.62% (24/111). The mutation F1174L (exon 23
position 3520) and the mutation F1174L (exon 23 posi-
tion 3522) were detected in 2 and 11 samples, respec-
tively, whereas the mutation R1275Q (exon 25 position
3824) was identified in 15 samples. The mutations
F1174L (exon 23 position 3522) and the mutation
R1275Q were detected in the same sample in four cases.
ALK mutation detection in tumor samples
by Sanger sequencing and ddPCR and
Illumina Deep sequencing
Among the 111 cases previously evaluable by ddPCR on
circulating DNA, the Sanger sequencing was performed
on 101 DNA tumor samples containing more than 50%
of malignant cells. The 10 other tumor samples were not
available or containing a low proportion of tumor cells.
Among the 101 tumors studied, the mutation F1174L
(exon 23) was identified in five cases and the mutation
R1275Q (exon 25) was detected in nine cases. All ALK
mutations detected by Sanger sequencing were also identi-
fied in circulating DNA. All ALK mutations were somatic
since no mutation was detected in corresponding normal
DNA samples (data not shown). The proportion of
mutated cases after analysis of DNA tumors samples by
Sanger sequencing was lower than the ratio of mutated
cases detected by ddPCR in plasma samples. Furthermore,
some mutations present in the plasma of patients were
also previously identified on cell lines established from
the same patient (patients’ nos. 1, 2, 15, 17, and 19) [3].
For these different reasons, we decided to study DNA
obtained from tumor samples using ddPCR system since
this technology was described to be highly sensitive.
Among the 101 tumors studied by Sanger sequencing, 60
samples (40 cases defined as WT for the two hotspots
and 20 samples defined mutated by ddPCR analysis on
circulating DNA samples) were selected and analyzed.
ddPCR confirmed the mutations identified by Sanger
sequencing but also identified eight additional mutations,
four were the mutation F1174L on exon 23 (one was spe-
cific of position 3520 and three were specific of position
3522) and four involved the mutation R1275Q on exon
25. Overall, a total of 17 patients showed one or two ALK
mutations after analysis of DNA tumor samples by
ddPCR (Table 2). In 40 tumor samples defined as WT
after analysis of circulating DNA, no mutation was found
in the hotspots of the exons 23 or 25. Mutant to WT
ALK ratio was ranged from 16.7% to 41% for the cases
identified by the ddPCR system and Sanger sequencing,
whereas it decreased to 0.07% for the samples detected
only by ddPCR.
To validate the data obtained by ddPCR, the tumors of
patients showing ALK mutations detected in plasma or
tumor samples were analyzed by deep sequencing using
Illumina HiSeq2500 technology in a blinded study. A
good concordance was observed between both techniques
although for two cases, mutations were only detected by
deep sequencing (PT4 (R1275Q, 3824,G>A) and PT14
(F1174L(3522,C>A) (Tables 2 and 3).
Comparison between the data obtained on
circulating DNA and DNA tumor samples
after ddPCR analysis
We found a perfect concordance for the analysis of
F1174L mutation (3520, T>C) between circulating DNA
and DNA tumor samples. Indeed, one case was positive
in blood and the tumor (PT1) and the other cases were
negative in DNA tumor samples and circulating DNA
samples. For the F1174L mutation (3522, C>A), in four
cases (patients’ nos. 3, 5, 7, and 24) this mutation was
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 543
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detected in blood but was not found in the tumor,
whereas one patient (no. 11) showed this mutation only
in tumor sample. For the 55 other cases, this hotspot was
defined as WT for 49 patients and mutated for six
patients in both circulating DNA and DNA tumors.
Finally, when we analyzed the hotspot R1275Q, 46 and 12
cases were found WT and mutated, respectively, in both
circulating DNA and DNA tumor samples, one case
showed this mutation only in the tumor (no. 6), whereas
for one other case the mutation was detected only in the
blood (no. 23) Overall, the sensitivity of our test for the
detection of F1174L mutations to position (3520, (T>C)
and 3522 (C>A)) and R1275Q mutation was 100%,
85.7%, and 92.3%, respectively, and the specificity was
100%, 92.4%, and 97.9%, respectively. The specificity and
the sensitivity of our assay may have been underestimated
since (1) the tumors analyzed in this study were microbi-
opsies obtained from primary tumor or metastatic site,
and (2) the tumors may be heterogeneous as shown
recently [23]. This last point was confirmed by the analy-
sis of the primary tumor (80% of malignant cells) and a
lymph node containing 70% of tumor cells for the
patient no. 21. The ratio of R1275Q mutation was 2.6%
and 20.2% in the primary tumor and the lymph node,
respectively.
Discussion
In this report, we present the feasibility of screening for
the presence of two hotspot ALK mutations in NB
patients by analysis of circulating DNA obtained from
200 lL of serum or plasma samples collected at diagnosis
using ddPCR system. The basis for successful circulating
DNA detection is the selection of an isolation method
that ensures extraction of a sufficient amount of quality
DNA. As shown by different teams [24, 25], the choice of
commercial kits is important and QIAampDNA Micro
Kit and QIAamp MinElute Virus Vacuum Kit (Qiagen)
were described as more suitable. We have confirmed these
results (data not shown). It was crucial for our study to
use a minimal quantity of blood, as it is difficult to col-
lect a large volume of blood since the patients with NB
tumors are young (age often below 7 years with a
majority being between 2 and 5 years). To our
knowledge, this is the first study showing the detection of
rare mutant alleles from only few milliliters (200 lL) of
serum or plasma. Overall, circulating DNA was isolated
from 114 patient blood samples and interpretable in 111
cases. The ALK mutation was identified in 21.62% of
patients. This high frequency of ALK mutations is
consistent with the previous study published by Sausen
et al. in which 10 cases showed ALK mutation among the
41 NB samples analyzed by next-generation sequencing
analysis [26].
Our aim was to compare the data obtained from circu-
lating DNA to the data obtained by Sanger sequencing
(exon 23 and exon 25) of tumor DNAs. Among the 111
cases, the Sanger sequencing was possible in 101 tumor
DNA samples containing >50% tumor cells. ALK mutation
was identified in 14 cases (13.8%). All ALK mutations
detected by Sanger sequencing were also identified in cir-
culating DNA. However, a large number of mutations
Figure 2. Representative bar graph of ddPCR analysis of plasma and control samples for identifying the R1275Q ALK mutation (the results of
duplicates were merged). The number of droplets positive is indicated at the top of each bar (in blue = droplets containing mutated DNA, in
green = droplets containing wild-type DNA). The bar in blue-green define the number of droplets analyzed (empty droplets + droplets containing
wild or mutated DNA).
546 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Detection of Tumor ALK Status V. Combaret et al.
Table 3. Base frequencies at the coordinates of interest in NB samples analyzed by deep sequencing (Illumina HiSeq 2500).
Chr position/patient ID Reads
T G C A
% P-value % P-value % P value % P value
F1174L 3520 T>C, chr2:29220831
Controls 79,7051 99.987 NA 0 NA 0.01 NA 0.003 NA
PT1 32,757 92.805 0.00E+00 0 NA 7.192 0.00E+00 0.003 NA
PT3 30,624 9999 NA 0 NA 0.01 NA 0 NA
PT4 32,998 99.979 NA 0.003 NA 0.009 NA 0.009 NA
PT5 35,142 99.98 NA 0 NA 0.017 NA 0.003 NA
PT6 34,977 99.977 NA 0.003 NA 0.011 NA 0.009 NA
PT7 37,846 99.976 NA 0 NA 0.021 NA 0.003 NA
PT8 37,000 99.986 NA 0 NA 0.011 NA 0.003 NA
PT10 31,101 99.987 NA 0.003 NA 0.006 NA 0.003 NA
PT11 18,320 99.989 NA 0,005 NA 0.005 NA 0 NA
PT14 31,871 99.991 NA 0.003 NA 0.006 NA 0 NA
PT15 44,349 99.982 NA 0.002 NA 0.014 NA 0.002 NA
PT16 35,523 99.989 NA 0.003 NA 0.006 NA 0.003 NA
PT17 31,232 99.99 NA 0 NA 0.01 NA 0 NA
PT18 34,764 99.974 NA 0 NA 0.023 NA 0.003 NA
PT19 36,172 99.981 NA 0 NA 0.014 NA 0.006 NA
PT21 35,015 99.991 NA 0 NA 0.009 NA 0 NA
PT21 22,403 99.987 NA 0 NA 0.004 NA 0.009 NA
PT22 42,150 99.988 NA 0 NA 0.009 NA 0.002 NA
PT23 36,548 99.984 NA 0 NA 0.014 NA 0.003 NA
PT23 37,033 99.989 NA 0 NA 0.005 NA 0.005 NA
PT24 31,343 99.987 NA 0 NA 0.01 NA 0.003 NA
F1174L 3522, C>A, chr2:29220829
Controls 796,257 0.009 NA 0.003 NA 99.976 NA 0.011 NA
PT1 32,732 0.009 NA 0.003 NA 99.985 NA 0.003 NA
PT3 30,566 0.003 NA 0 NA 99.977 NA 0.02 NA
PT4 32,908 0.015 NA 0.006 NA 53.27 0.00E+00 46.709 0.00E+00
PT5 35,113 0.014 NA 0 NA 99.974 NA 0.011 NA
PT6 34,885 0.011 NA 15.055 0.00E+00 64.718 0.00E+00 20.212 0.00E+00
PT7 37,824 0.003 NA 0 NA 99.989 NA 0.008 NA
PT8 36,884 0.005 NA 0.005 NA 61.463 0.00E+00 38.521 0.00E+00
PT10 31,071 0.003 NA 0 NA 99.99 NA 0.006 NA
PT11 18,266 0.011 NA 0 NA 97.64 0.00E+00 2.349 0.00E+00
PT14 31,840 0.009 NA 0 NA 99.846 3.37E-16 0.144 1.66E-25
PT15 44,301 0.007 NA 0 NA 99.989 NA 0.002 NA
PT16 35,485 0.014 NA 0.003 NA 99.969 NA 0.011 NA
PT17 31,207 0 NA 0.003 NA 99.99 NA 0.006 NA
PT18 34,734 0.014 NA 0.003 NA 99.977 NA 0.006 NA
PT19 36,146 0.019 NA 0.011 NA 99.967 NA 0.003 NA
PT21 34,986 0.009 NA 0.003 NA 90.896 0.00E+00 9.089 0.00E+00
PT21 22,338 0.004 NA 0 NA 99.624 1.04E-56 0.367 1.16E-74
PT22 42,101 0.012 NA 0.002 NA 99.929 2.70E-01 0.05 3.41E-02
PT23 36,413 0.014 NA 0.003 NA 62.722 0.00E+00 37.259 0.00E+00
PT23 36,925 0.008 NA 0 NA 75.355 0.00E+00 24.636 0.00E+00
PT24 31319 0.003 NA 0 NA 99.987 NA 0.006 NA
R1275Q 3824 G>A, chr2:29209798
Controls 1,005,867 0.016 NA 99.956 NA 0.001 NA 0.027 NA
PT1 49,218 0.008 NA 99.974 NA 0 NA 0.018 NA
PT3 53,946 0.011 NA 99.972 NA 0.002 NA 0.015 NA
PT4 51,659 0.006 NA 99.783 1.41E-31 0 NA 0.211 3.33E-46
PT5 73,384 0.022 NA 99.95 NA 0.001 NA 0.027 NA
PT6 68,439 0.013 NA 98.004 0.00E+00 0.001 NA 1.981 0.00E+00
(Continued)
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found in plasma were not identified by Sanger sequenc-
ing. This technique is described to be less sensitive (20%)
[27] than the ddPCR system [13]. Therefore, the ddPCR
was used to analyze DNA tumors obtained from 60 spec-
imens. Additional mutations were found with this proce-
dure and the results obtained by ddPCR were validated
using a deep sequencing method. The codetection of two
mutations was only detectable with highly sensitive meth-
ods. The presence of two different mutations in the same
patient has been previously reported [4, 5]. The heteroge-
neity of tumors can explain the detection of these two
mutations found in different subclones present in the
same NB sample or in different tumor specimens (pri-
mary tumor or distant metastases) found in the same
patient. Among the 24 patients shown in Table 2, differ-
ent cases illustrate well these suggestions. For the patient
no. 21, the primary tumor containing 80% of tumor cells
showed 2.6% of R1275Q mutation, whereas this mutation
was found at a ratio of 20.2% in lymph node showing
70% of tumor cells. This case shows that the distribution
of the mutated population varies among different tumor
sites. Chan et al. have shown that cell-free DNA frag-
ments from multiple lesions in the same individual all
mix together in the peripheral blood [28]. The codetec-
tion of two mutations was also observed in circulating
DNA samples therefore ddPCR mutation detection in free
circulating DNA may overcome issues of tumor heteroge-
neity and detect rare mutations which might not be iden-
tified by studying a single site of disease. For example, in
the patient no. 23, both F1174L (exon 23 position 3522)
and R1275Q mutations are detected in plasma sample
but only the F1174L mutation was found in primary
tumor. For this case, the R1275Q was not detected on
primary tumor at diagnosis or after chemotherapy but
perhaps this mutation was present on metastatic sites.
Unfortunately, no biopsy or puncture obtained from
metastatic sites was available.
To our knowledge, this retrospective study is the first
study evaluating the feasibility of ddPCR to identify the
presence of hotspot ALK mutations in NB patients by
analysis of free circulating DNA. To identify the other
ALK mutations specific of NB tumors as detected for
patients PT6 (3522, C>G) and PT11 (3824, G>T) by deep
sequencing (Table 3), other ddPCR assays are currently in
development. New protocols based on ALK-targeted ther-
apy by crizotinib or other ALK targeting molecules have
opened for the treatment of NB patients in relapse if their
tumors showed mutation and/or amplification of the ALK
gene and new tumor sampling is strongly recommended
at the time of relapse [23] for evaluating ALK mutational
status given the observation that an emergence of ALK
mutation might be seen at relapse. As biopsy or puncture
of the tumor at this time of the disease is not always pos-
sible or does not permit to collect enough material for
deep sequencing analysis, the study of free circulating
DNA by ddPCR appears as a reliable, noninvasive blood
test to assess ALK mutational status at F1174 and R1275
hotspots. Currently, it is too early to know whether criz-
otinib will be effective in children who harbor somatic
ALK mutations [12]. The assays performed in vitro and
in xenograft models have shown that the two mutations,
R1275Q and F1174L found in NB tumors, display a dif-
ferent sensitivity to crizotinib, the first being responder to
crizotinib and the latter being resistant [10]. The reduced
Table 3. Continued.
Chr position/patient ID Reads
T G C A
% P-value % P-value % P value % P value
PT7 49,685 0.002 NA 99.964 NA 0.002 NA 0.032 NA
PT8 52,130 0.006 NA 99.969 NA 0 NA 0.025 NA
PT10 50,187 0.01 NA 53.265 0.00E+00 0.004 NA 46.715 0.00E+00
PT11 46,445 2.119 0.00E+00 88.937 0.00E+00 0 NA 8.942 0.00E+00
PT14 27,110 0 NA 75.393 0.00E+00 0.007 NA 24.592 0.00E+00
PT15 34,878 0.011 NA 73.195 0.00E+00 0.003 NA 26.788 0.00E+00
PT16 47,751 0.013 NA 52.667 0.00E+00 0.004 NA 47.31 0.00E+00
PT17 56,685 0.023 NA 76.465 0.00E+00 0 NA 23.512 0.00E+00
PT18 52,198 0 NA 65.732 0.00E+00 0.004 NA 34.262 0.00E+00
PT19 55,451 0.005 NA 50.333 0.00E+00 0.002 NA 49.651 0.00E+00
PT21 51,696 0.006 NA 97.373 0.00E+00 0 NA 2.621 0.00E+00
PT21 44,126 0.005 NA 76.069 0.00E+00 0 NA 23.925 0.00E+00
PT22 48,821 0.006 NA 53.327 0.00E+00 0 NA 46.662 0.00E+00
PT23 52,852 0.011 NA 99.97 NA 0 NA 0.019 NA
PT23 59,037 0.007 NA 99.978 NA 0 NA 0.015 NA
PT24 51,971 0.01 NA 99.835 1.59E-16 0 NA 0.156 9.57E-26
The mutations detected by deep sequencing and ddPCR are indicated in bold.
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susceptibility of F1174L mutated ALK to crizotinib inhibi-
tion results from an increase in ATP binding affinity,
suggesting that higher doses of crizotinib may mitigate
the resistance. Another promising strategy using PI3K/
AKT/mTOR pathway inhibitors in combination with criz-
otinib has been suggested recently for the treatment of
NB patients showing ALKF1174L mutation [29]. In conse-
quence, the treatment should be conducted according to
ALK mutational status. The analysis of circulating DNA
by ddPCR should help clinicians to identifying the
patients who might benefit from ALK-targeted therapy
and to defining which treatment should be performed.
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